Cioteronel
- None
- 4-(5-methoxyheptyl)-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-one
- 89672-11-7
- 55994
- 50555
- 1RTH95874Z
- ChEMBL2104105
- Interactive image
- CCC(CCCCC1CCC2C1CC(=O)C2)OC
- InChI=InChI=1S/C16H28O2/c1-3-15(18-2)7-5-4-6-12-8-9-13-10-14(17)11-16(12)13/h12-13,15-16H,3-11H2,1-2H3
- Key:KDULJHFMZBRAHO-UHFFFAOYSA-N
Cioteronel (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name) (developmental code name CPC-10997; former tentative brand names Cyoctol, X-Andron) is a nonsteroidal antiandrogen (NSAA) that was never marketed.[1][2][3] It was under development between 1989 and 2001 for the topical treatment of androgenetic alopecia (male pattern baldness), and acne and for the oral treatment of benign prostatic hyperplasia; it reached phase III clinical trials for acne and phase II studies for androgenetic alopecia, but was ultimately discontinued due to poor efficacy.[3][4]
See also
References
- ^ Ganellin CR, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. p. 570. ISBN 978-0-412-46630-4.
- ^ Lednicer D (21 November 1994). The Organic Chemistry of Drug Synthesis. John Wiley & Sons. pp. 11–. ISBN 978-0-471-58959-4.
- ^ a b Tiwari A, Krishna NS, Nanda K, Chugh A (November 2005). "Benign prostatic hyperplasia: an insight into current investigational medical therapies". Expert Opinion on Investigational Drugs. 14 (11): 1359–72. doi:10.1517/13543784.14.11.1359. PMID 16255676. S2CID 25662071.
- ^ "Cioteronel". Adis Insight. Springer Nature Switzerland AG. Archived from the original on 2016-12-29. Retrieved 2016-11-25.
- v
- t
- e
Agonists |
|
---|
- See also
- Receptor/signaling modulators
- Androgens and antiandrogens
- Estrogen receptor modulators
- Progesterone receptor modulators
- List of androgens and anabolic steroids
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e